HK1202415A1 - Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof - Google Patents

Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof Download PDF

Info

Publication number
HK1202415A1
HK1202415A1 HK15101975.0A HK15101975A HK1202415A1 HK 1202415 A1 HK1202415 A1 HK 1202415A1 HK 15101975 A HK15101975 A HK 15101975A HK 1202415 A1 HK1202415 A1 HK 1202415A1
Authority
HK
Hong Kong
Prior art keywords
ohepa
hetre
dgla
methods
pharmaceutical compositions
Prior art date
Application number
HK15101975.0A
Other languages
English (en)
Chinese (zh)
Inventor
John Climax
David Coughlan
Mehar Manku
Original Assignee
Dignity Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Limited filed Critical Dignity Sciences Limited
Publication of HK1202415A1 publication Critical patent/HK1202415A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38—Percompounds, e.g. peracids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15101975.0A 2011-10-19 2012-10-19 Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof HK1202415A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549018P 2011-10-19 2011-10-19
US61/549,018 2011-10-19
PCT/EP2012/070809 WO2013057284A1 (en) 2011-10-19 2012-10-19 Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1202415A1 true HK1202415A1 (en) 2015-10-02

Family

ID=46796104

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101975.0A HK1202415A1 (en) 2011-10-19 2012-10-19 Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof

Country Status (5)

Country Link
US (2) US8293790B2 (https=)
EP (1) EP2768495A1 (https=)
JP (2) JP2014530840A (https=)
HK (1) HK1202415A1 (https=)
WO (1) WO2013057284A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA39718A (fr) * 2014-04-09 2017-02-15 Dignity Sciences Ltd Compositions et méthodes d'utilisation de celles-ci
WO2015172801A1 (en) * 2014-05-12 2015-11-19 Unilever N.V. Niacinamide for inducing generation of antimicrobial peptides
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA47141A (fr) * 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
US20200206173A1 (en) 2017-08-30 2020-07-02 Conopco, Inc., D/B/A Unilever A personal care composition
US11504327B1 (en) 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
FR3148365A1 (fr) * 2023-05-04 2024-11-08 Pierre Fabre Dermo-Cosmetique Oxylipines dans le traitement de la séborrhée et/ou de l’acné

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5264452A (en) 1975-11-18 1977-05-27 Nippon Suisan Kaisha Ltd Method of producing processed fish meat
JPS5820575B2 (ja) 1975-11-27 1983-04-23 日本水産株式会社 スイサンカコウヒンノセイゾウホウ
US4273763A (en) 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
US4444755A (en) 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
DE2967049D1 (en) 1978-04-11 1984-07-19 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
IE51145B1 (en) 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
IE53332B1 (en) 1980-03-14 1988-10-26 Efamol Ltd Pharmaceutical compositions
US4386072A (en) 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
US5324748A (en) 1981-07-14 1994-06-28 Efamol Limited Method for enhancement of 1-series PG production
US5145686A (en) 1982-02-03 1992-09-08 Efamol Limited Topical pharmaceutical compositions
DE3363567D1 (en) 1982-03-01 1986-06-26 Efamol Ltd Pharmaceutical and dietary composition
EP0087865B1 (en) 1982-03-01 1986-10-01 Efamol Limited Pharmaceutical composition
DE3366838D1 (en) 1982-03-01 1986-11-20 Efamol Ltd Pharmaceutical composition
IE54795B1 (en) 1982-04-29 1990-02-14 Efamol Ltd Pharmaceutical composition
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
GB8326130D0 (en) 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
GB8420771D0 (en) 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
GB8425006D0 (en) 1984-10-03 1984-11-07 Efamol Ltd Composition of copper/fatty acids
GB8506027D0 (en) 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
GB8522670D0 (en) 1985-09-13 1985-10-16 Efamol Ltd Drug treatments
GB8524275D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
EP0309086A1 (en) 1987-09-07 1989-03-29 Efamol Holdings Plc Treatment of male pattern baldness and of unwanted hair growth
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
US5352700A (en) 1988-01-14 1994-10-04 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of infantile seborrheic eczema
GB8806737D0 (en) 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
GB8916734D0 (en) 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
GB8920228D0 (en) 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
JPH04290820A (ja) 1991-03-18 1992-10-15 Idemitsu Petrochem Co Ltd 皮膚病犬の治療方法とその薬剤
KR930006432B1 (ko) 1991-04-10 1993-07-16 주식회사 우방랜드 아이코사펜타노산 및 α-리놀렌산을 함유하는 여드름 치료제 조성물
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
GB9112052D0 (en) 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
US5605929A (en) * 1992-05-27 1997-02-25 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
GB9211229D0 (en) 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
US5409955A (en) 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
GB9403855D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US5709855A (en) 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
GB9621373D0 (en) 1996-10-14 1996-12-04 Scotia Holdings Plc Fatty acid treatment
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
AU6503699A (en) 1998-10-05 2000-04-26 Abbott Laboratories Altered fatty acid biosynthesis in insect cells using delta five desaturase
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
CA2304906A1 (en) 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
ATE291910T1 (de) 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
US20030073930A1 (en) 2001-10-17 2003-04-17 Morrissey Gerald R. Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females
US20030105445A1 (en) 2001-11-30 2003-06-05 Kimberly-Clark Worldwide, Inc. Breast pad assembly containing a skin benefit ingredient
US20030194446A1 (en) 2002-04-10 2003-10-16 Akes Lindy K. Zinc oxide compositions for dermatheraputics
AU2003299034A1 (en) 2002-09-20 2004-04-08 Griscom Bettle Iii Transdermal compositions
DE102004031210A1 (de) 2004-06-28 2006-02-09 Trommsdorff Gmbh & Co. Kg MLV-Kosmetikum
US20050148495A1 (en) * 2003-07-23 2005-07-07 Lambert Lewis H.Jr. Methods and materials including for treating acne
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
DK1756280T3 (en) 2004-04-22 2015-02-02 Commw Scient Ind Res Org SYNTHESIS OF CHAIN, polyunsaturated fatty acids BY RECOMBINANT CELLS
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
EP3581178B1 (en) 2005-02-14 2023-08-30 Suntory Holdings Limited Composition containing dihomo-(gamma)-linolenic acid (dgla) as active ingredient
JP2006306812A (ja) 2005-04-28 2006-11-09 Suntory Ltd 好酸球浸潤抑制剤
JP5546087B2 (ja) 2005-02-14 2014-07-09 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
CA2674210A1 (en) 2005-12-30 2007-07-12 Intradigm Corporation Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment
CA2649337C (en) 2006-04-13 2014-11-18 Nippon Suisan Kaisha, Ltd. Process for preparing concentrated polyunsaturated fatty acid oil
GB0611240D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
FR2906716B1 (fr) 2006-10-06 2013-05-17 Clarins Lab Utilisation d'une composition cosmetique pour le soin des peaux grasses.
US20080125487A1 (en) 2006-11-17 2008-05-29 Tapas Das Elongase gene and uses thereof
WO2008070129A2 (en) 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
JP2010512757A (ja) 2006-12-20 2010-04-30 プロテック リサーチ ピーティーワイ リミテッド リポキシゲナーゼの抽出および精製
US20080213357A1 (en) 2007-02-12 2008-09-04 Andrew Bruce Hebard Plant Derived Lipid Useful for Nutraceutical and Cosemeceutical Applications
ITMI20070555A1 (it) 2007-03-21 2007-06-20 Giuliani Spa Composizione provvista di attivita' di inibizione sulla 5 alfa-reduttasi
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009130291A2 (de) 2008-04-25 2009-10-29 Basf Plant Science Gmbh Pflanzensamenöl
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
GB0907601D0 (en) 2009-05-01 2009-06-10 Equateq Ltd Novel methods
US8637298B2 (en) 2009-06-16 2014-01-28 E I Du Pont De Nemours And Company Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production
US8188335B2 (en) 2009-07-17 2012-05-29 Abbott Laboratories Δ9-elongase for production of polyunsaturated fatty acid-enriched oils
US20110082216A1 (en) 2009-10-02 2011-04-07 Wu Jeffrey M Benzoyl peroxide composition for treating skin
AU2011349718B2 (en) 2010-12-21 2017-02-09 Nestec S.A. Methods and compositions for preventing and treating osteoarthritis
EP2508180A1 (en) 2011-04-04 2012-10-10 Nestec S.A. Sn-1(3) Monoacylglycerides and lipid absorption
RU2014119948A (ru) 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same

Also Published As

Publication number Publication date
US20120232147A1 (en) 2012-09-13
JP2017226664A (ja) 2017-12-28
JP2014530840A (ja) 2014-11-20
WO2013057284A1 (en) 2013-04-25
US9056086B2 (en) 2015-06-16
EP2768495A1 (en) 2014-08-27
US20130102575A1 (en) 2013-04-25
US8293790B2 (en) 2012-10-23

Similar Documents

Publication Publication Date Title
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof
HK1198921A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
IN2014DN07483A (https=)
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
NZ611606A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP4667051A3 (en) Composition suitable for human consumption comprising decanoic acid and octanoic acid
WO2015077503A8 (en) Autotaxin inhibitor compounds
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
CL2012002013A1 (es) Microorganismos aislado thrastochytrium sp. atcc pta-10212 util en la produccion de acidos grasos omega-3
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP2275104A3 (en) Pharmaceutical and cosmetic composition including lactoferrin, ciclopirox and etidronic acid
WO2015061632A3 (en) Antimicrobial compositions and articles
NZ596228A (en) Compositions and methods for the treatment of inflammation
WO2013116753A8 (en) Fatty acids as anti-inflammatory agents
HK1210417A1 (en) Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders
PH12016501159B1 (en) Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
EP2709455A4 (en) PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
EP2801356A3 (en) DHA and EPA for the reduction of oxidative stress